STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

  1. Home
  2. Sec-filings
  3. JAGX
  4. [EFFECT] Jaguar Health, Inc. SEC Filing

[EFFECT] Jaguar Health, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: June 27, 2025 4:00 P.M.
Form: S-3
CIK: 0001585608
Company Name: Jaguar Health, Inc.
File Number: 333-288202

Source: View Original Filing on SEC EDGAR

Stock JAGX logo
Jaguar Health Inc

NASDAQ:JAGX

JAGX Rankings

#6606 Ranked by Market Cap
N/A Ranked by Dividends

JAGX Latest News

Nov 24, 2025
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
Nov 20, 2025
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
Nov 17, 2025
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Nov 14, 2025
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
Nov 13, 2025
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

JAGX Latest SEC Filings

Nov 25, 2025
[424B3] Jaguar Health, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)
Nov 19, 2025
[8-K] Jaguar Health, Inc. Reports Material Event
Nov 14, 2025
[8-K] Jaguar Health, Inc. Reports Material Event
Nov 14, 2025
[10-Q] Jaguar Health, Inc. Quarterly Earnings Report
Nov 10, 2025
[DEF 14A] Jaguar Health, Inc. Definitive Proxy Statement

JAGX Stock Data

4.74M
2.74M
34.76%
0.63%
3.04%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO